What Analysts Are Saying About Chemours Stock
5 analysts have shared their evaluations of Chemours (NYSE:CC) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 1 | 3 | 0 | 0 |
| Last 30D | 0 | 1 | 2 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 1 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $17.4, a high estimate of $21.00, and a low estimate of $13.00. This current average reflects an increase of 7.41% from the previous average price target of $16.20.
Breaking Down Analyst Ratings: A Detailed Examination
The analysis of recent analyst actions sheds light on the perception of Chemours by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| John McNulty | BMO Capital | Lowers | Outperform | $19.00 | $20.00 |
| Jeffrey Zekauskas | JP Morgan | Raises | Neutral | $17.00 | $13.00 |
| Vincent Andrews | Morgan Stanley | Raises | Equal-Weight | $17.00 | $15.00 |
| Peter Osterland | Truist Securities | Raises | Buy | $21.00 | $18.00 |
| Jeffrey Zekauskas | JP Morgan | Lowers | Neutral | $13.00 | $15.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Chemours. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Chemours compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Chemours's stock. This comparison reveals trends in analysts' expectations over time.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Chemours's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Chemours analyst ratings.
About Chemours
The Chemours Co is a provider of chemicals. It delivers customized solutions with a wide range of industrial and specialty chemicals products for various markets including coatings, plastics, refrigeration, air conditioning, etc. The company's operating segments include Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. It generates maximum revenue from the Titanium Technologies segment. The Titanium Technologies segment is a producer of TiO2 pigment, a premium white pigment used to deliver whiteness, brightness, opacity, durability, efficiency, and protection across a variety of applications. Geographically, the company derives a majority of its revenue from North America.
Chemours's Economic Impact: An Analysis
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Chemours's revenue growth over a period of 3M has faced challenges. As of 30 September, 2025, the company experienced a revenue decline of approximately -0.86%. This indicates a decrease in the company's top-line earnings. When compared to others in the Materials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Chemours's net margin is impressive, surpassing industry averages. With a net margin of 4.01%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Chemours's ROE stands out, surpassing industry averages. With an impressive ROE of 22.43%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Chemours's ROA stands out, surpassing industry averages. With an impressive ROA of 0.8%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 14.82, caution is advised due to increased financial risk.
The Significance of Analyst Ratings Explained
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.